Krsnaa Diagnostics cash flow

Latest FY26

Cash from operations: ₹143cr+63.9% on FY25
Capital spending: ₹219cr+73.2% on FY25
Free cash flow: −₹76.2cr−₹39.3 cr in FY25
Cash from financing: ₹279cr+1,930.6% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	90.5	88.3	74.5	53.8
	—	0.0	0.9	0.0	0.0
	—	34.4	24.7	16.5	7.7
	—	−15.2	−15.3	−15.2	−15.9
	—	−25.9	0.0	0.0	0.0
	—	2.2	4.0	0.9	0.0
	—	0.1	0.0	0.0	0.0
	—	0.9	0.0	−7.2	−0.6
	—	0.1	−4.6	0.1	−0.2
	—	2.8	6.3	−10.7	−15.9
	—	−18.4	−102	−104	−14.4
	—	8.1	−13.3	−5.8	7.2
	—	2.7	2.4	0.4	−1.9
	—	−3.7	−4.0	0.3	0.6
	—	−3.9	−0.1	−9.0	0.9
	—	−43.8	19.4	15.7	−16.7
	—	2.7	−1.1	4.1	−25.0
	—	0.0	0.0	2.4	27.8
	—	3.3	−3.8	7.0	0.3
	—	0.0	0.0	0.0	−0.1
	—	3.7	3.1	0.0	0.0
	—	0.0	0.0	2.8	1.7
Cash from operating activities
	125	130	103	70.0	80.2
	—	40.3	4.6	−26.9	9.2
	—	171	107	43.1	89.4
	—	27.6	19.9	18.8	13.1
	—	143	87.3	24.3	76.3
Cash from investing activities
	—	219	127	194	141
	—	3.7	14.9	0.9	6.6
	—	0.0	31.3	0.0	0.0
	—	−189	25.4	53.7	15.7
	—	8.5	17.9	10.4	10.1
	—	−396	−99.6	−129	−109
Cash from financing activities
	—	3.8	0.0	23.2	0.0
	—	417	0.0	0.0	0.0
	—	−92.4	58.8	95.7	0.0
	—	0.0	0.0	5.5	9.1
	—	14.0	15.9	8.2	4.0
	—	26.6	21.1	12.4	5.3
	—	8.9	8.1	8.6	7.8
	—	0.0	0.0	0.0	−6.9
	—	279	13.8	84.2	−33.1
	—	26.4	1.5	−20.3	−65.7
	—	26.4	1.5	−20.3	−65.7
	—	—	—	2.4	22.7
Reference items
	218	212	190	144	122
	26.8%	27.4%	26.5%	23.3%	25.1%
	−76.2	−76.2	−39.3	−170	−65.1
	—	228	−16.6	−54.6	—
	−₹23.48	−₹23.48	−₹12.12	−₹52.27	−₹20.06
	—	1.41×	1.13×	0.43×	1.23×
	—	27.6	19.9	18.8	13.1
	—	26.6	21.1	12.4	5.3

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

KRSNAA₹497.95

Krsnaa Diagnostics Limited

· Pharma & Health

₹ CrorePeersSURAKSHA HEALTHX NEPHROPLUS 3BBLACKBIOMcap ₹1,615 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	53.8	74.5	88.3	90.5	—
+ Impairment Loss / (Reversal)	0.0	0.0	0.9	0.0	—
+ Finance Costs	7.7	16.5	24.7	34.4	—
+ Interest Income	-15.9	-15.2	-15.3	-15.2	—
+ Fair Value (Gains) / Losses	0.0	0.0	0.0	-25.9	—
+ Share-based Payments	0.0	0.9	4.0	2.2	—
+ Undistributed Profits of Associates	0.0	0.0	0.0	0.1	—
+ Other Non-cash Items	-0.6	-7.2	0.0	0.9	—
+ Other — Cash Effects are Investing / Financing	-0.2	0.1	-4.6	0.1	—
Changes in Working Capital
+ Inventories	-15.9	-10.7	6.3	2.8	—
+ Trade Receivables — Current	-14.4	-103.5	-102.3	-18.4	—
+ Other Financial Assets — Current	7.2	-5.8	-13.3	8.1	—
+ Other Financial Assets — Non-current	-1.9	0.4	2.4	2.7	—
+ Other Current Assets	0.6	0.3	-4.0	-3.7	—
+ Other Non-current Assets	0.9	-9.0	-0.1	-3.9	—
+ Trade Payables — Current	-16.7	15.7	19.4	-43.8	—
+ Other Financial Liabilities — Current	-25.0	4.1	-1.1	2.7	—
+ Other Financial Liabilities — Non-current	27.8	2.4	0.0	0.0	—
+ Other Current Liabilities	0.3	7.0	-3.8	3.3	—
+ Other Non-current Liabilities	-0.1	0.0	0.0	0.0	—
+ Provisions — Current	0.0	0.0	3.1	3.7	—
+ Provisions — Non-current	1.7	2.8	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	80.2	70.0	102.7	130.4	125.5
+ Total Adjustments (incl. Working Capital)	9.2	-26.9	4.6	40.3	—
Cash from Operations (pre-tax)	89.4	43.1	107.3	170.7	—
+ Income Taxes Paid	13.1	18.8	19.9	27.6	—
Cash from Operating Activities	76.3	24.3	87.3	143.1	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	141.4	193.9	126.6	219.3	—
+ Disp of Fixed Assets	6.6	0.9	14.9	3.7	—
+ Acq of Subsidiaries / Businesses (net)	0.0	0.0	31.3	0.0	—
+ Loans & Advances Repaid	15.7	53.7	25.4	-188.9	—
+ Interest Received — Investing	10.1	10.4	17.9	8.5	—
Cash from Investing Activities	-108.9	-128.9	-99.6	-396.0	—
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options	0.0	23.2	0.0	3.8	—
+ Proceeds from Debentures / Notes / Bonds	0.0	0.0	0.0	417.4	—
+ Proceeds from Borrowings	0.0	95.7	58.8	-92.4	—
+ Repayment of Borrowings	9.1	5.5	0.0	0.0	—
+ Payment of Lease Liabilities	4.0	8.2	15.9	14.0	—
+ Interest Paid	5.3	12.4	21.1	26.6	—
+ Dividends Paid	7.8	8.6	8.1	8.9	—
+ Other Inflows / (Outflows) — Financing	-6.9	0.0	0.0	0.0	—
Cash from Financing Activities	-33.1	84.2	13.8	279.3	—
Net Changes in Cash (pre-FX)	-65.7	-20.3	1.5	26.4	—
Net Changes in Cash	-65.7	-20.3	1.5	26.4	—
Closing Cash	22.7	2.4	—	—	—
Reference Items
EBITDA	122.3	144.2	190.1	211.9	218.5
EBITDA Margin %	25.11	23.28	26.51	27.42	26.79
Free Cash Flow (CFO − Capex)	-65.1	-169.5	-39.3	-76.2	-76.2
Free Cash Flow to Equity	—	-54.6	-16.6	228.1	—
Free Cash Flow per Basic Share	-20.06	-52.27	-12.12	-23.48	-23.48
Cash Flow to Net Income	1.23	0.43	1.13	1.41	—
Cash Paid for Taxes	13.1	18.8	19.9	27.6	—
Cash Paid for Interest	5.3	12.4	21.1	26.6	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.